Vince D. Cataldo, MD
Department of General Oncology, Division of Cancer Medicine
About Dr. Vince Cataldo
Dr. Cataldo, a Medical Oncologist and Hematologist has an extensive practice that includes the treatment of solid organ cancers and benign and malignant hematologic disorders. Originating from South Louisiana, Dr. Cataldo earned his medical degree from Louisiana State University Health Sciences Center in New Orleans in 2002. He completed his residency and chief residency in Internal Medicine at Louisiana State University in New Orleans, serving as the last chief resident of Charity Hospital at the time of its permanent closure due to Hurricane Katrina. After his chief residency, Dr. Cataldo completed his Hematology and Medical Oncology Fellowship training at MD Anderson Cancer Center, significantly adding to his extensive experience. He then returned to Baton Rouge, where he focused on resident and medical student education. In 2025, Dr. Cataldo returned to MD Anderson as the Fellowship Program Director of the Hematology and Medical Oncology Fellowship Training Program. He also serves on the Approval Committee for the Hematology Board of the American Board of Internal Medicine. Additionally, Dr. Cataldo is a fellow of the American College of Physicians and a member of the American Society of Clinical Oncology and the American Society of Hematology.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Program Director, Department of Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Program Director, Department of Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2002 | Louisiana State University, Health Sciences Center, New Orleans, Louisiana, US, Medicine, Doctorate of Medicine |
| 1997 | Louisiana State University, Baton Rouge, Louisiana, US, Zoology, Bachelor of Science |
Postgraduate Training
| 2008-2009 | Chief Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2008 | Chief Fellow, Education, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2006-2007 | Postgraduate Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2006 | Chief Residency, Louisiana State University, New Orleans, Louisiana |
| 2003-2005 | Clinical Residency, Louisiana State University, New Orleans, Louisiana |
| 2002-2003 | Clinical Internship, Louisiana State University, New Orleans, Louisiana |
Experience & Service
Academic Appointments
Adjunct Associate Professor, Department of Physics and Astronomy, Louisiana State University, Baton Rouge, Louisiana, 2018 - 2025
Adjunct Assistant Professor, Department of School of Medicine, Tulane University, New, Orleans, 2013 - 2025
Associate, Our Lady of the Lake Physicians Group, Baton Rouge, Louisiana, 2012 - 2025
Associate, Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, 2009 - 2012
Associate Professor of Clinical Medicine, Department of Internal Medicine, Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, 2009 - 2025
Administrative Appointments/Responsibilities
Committee Member, American Board of Internal Medicine, Philadelphia, Pennsylvania, 2023 - Present
Mentor, Item-Writing Task Force, American Board of Internal Medicine, Philadelphia, Pennsylvania, 2023 - Present
Awards Committee - Chair, Department of Louisiana Chapter, American College of Physicians, Baton Rouge, Louisiana, 2023 - 2025
Nominations Committee - Chair, Department of Louisiana Chapter, American College of Physicians, Baton Rouge, Louisiana, 2022 - 2025
Item-Writing Task Force, American Board of Internal Medicine, Philadelphia, Pennsylvania, 2020 - 2024
Section Chief, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, 2020 - 2025
Chair, Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, 2016 - 2021
Section Chief, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, 2015 - 2017
Board of Governors, Department of Louisiana Chapter, American College of Physicians, Baton Rouge, Louisiana, 2015 - 2021
Special Committee, American College of Physicians, Philadelphia, Pennsylvania, 2014 - 2014
Section Chief, Baton Rouge General Medical Center, Baton Rouge, Louisiana, 2012 - 2015
Moderator, Our Lady of the Lake Cancer Center, Baton Rouge, Louisiana, 2009 - 2025
Institutional Committee Activities
Member, Our Lady of the Lake, Board of Directors, 2024 - 2025
Member, Medical Executive Committee, 2023 - 2025
Member, System-wide Pharmacy and Therapeutics Committee, 2020 - 2025
Chair, Pharmacy and Therapeutics Committee, 2013 - 2025
Honors & Awards
| Moses Maimonides Award for Ethics in Medicine, LSU Health Sciences Center | |
| Resident Teaching Award, LSU School of Medicine, Department of Internal Medicine | |
| Resident of the Year, Medical Center of Louisiana | |
| Alpha Omega Alpha, National Medical Honor Society | |
| Resident Teacher of the Year, LSU School of Medicine, Aesculapian Society | |
| Lyndon B. Johnson Fellow of the Year, MD Anderson Cancer Center | |
| Fellow of the American College of Physicians, American College of Physicians |
Selected Publications
Peer-Reviewed Articles
- Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9):None, 2021. PMID: 33946504.
- Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR Jr, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Trials 22(1):221, 2021. PMID: 33743799.
- Schroeder J, O'Neal C, Cataldo V. MASSIVE PULMONARY EMBOLISM: A RARE PRESENTATION OF ACUTE HIV-1 INFECTION. J La State Med Soc 167(3):155-6, 2015. PMID: 27159481.
- Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 2013. PMID: 23276888.
- Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama AA. A. Erlotinib or Gefitinib for Non- Small-Cell Lung Cancer-Correspondence. N Engl J Med 364(24):2367-2368, 2011. PMID: None.
- Cataldo VD. What Hippocrates knew about hurricane Katrina: observations of the chief resident. Am J Med Sci 332(5):301-2, 2006. PMID: 17106310.
Other Articles
- Kennedy-LeJeune E, Cataldo VD Kaposi's Sarcoma of the Oral Cavity. N Engl J Med 376(13):1268, 2017. PMID: 28355516.
- Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364(10):947-55, 2011. PMID: 21388312.
- Cataldo VD, Cortes J, Quintas-Cardama A Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 9(7):875-84, 2009. PMID: 19589026.
- Quintas-Cardama A, Kim TD, Cataldo V, Le Coutre P Nilotinib. Recent Results Cancer Res 184(None):103-17, 2009. PMID: 20072834.
- Mills TA, Kawji MM, Cataldo VD, Pappas ND, O'Meallie LP, Breaux DM, Glancy DL Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs. J La State Med Soc 156(6):327-31, 2004. PMID: 15688675.
- Stellingworth M, Broussard A, Cataldo V, Morrissey JR, Lipscomb G, Lopez FA, Rigby P Clinical case of the month. Weakness in an 88-year-old man. Multiple myeloma. J La State Med Soc 155(2):84-9; quiz 89-90, 119, 2003. PMID: 12778991.
Abstracts
- Kennedy-LeJeune E, O'Neal H, MSc MD, Miles L, Cataldo VD. Does Race Impact Survival in Multiple Myeloma. Blood 132(I):None, 2018. PMID: None.
- Westin J, Hagemeister F, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Kwak L, Lymphoma/Myeloma. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. J Clin Oncol 28(15):None, 2010. PMID: None.
- Westin JR, Thompson MA, Cataldo V, Bela B, Sanjorjo P, Bourgeois S, Murphy WA, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Hagemeister FB. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood 114(22):None, 2009. PMID: None.
- Cataldo VD, Thompson MA, Bekele B, Jimenez C, Huen AO, PharmD, Arbuckle RB, PharmD, Fanale MA, Fayad LE, Fowler N, Kwak LW, McLaughlin PW, Saatva N, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid. Blood 112(11):5297, 2008. e-Pub 2008. PMID: None.
- Cataldo V, Shah P, Wang X, Champlin R, Ueno N. Hyperglycemia in the Peri-transplant Period: A Modifiable Risk Factor for Infection. J Clin Oncol 26(15):None, 2008. e-Pub 2008. PMID: None.
Book Chapters
- Cataldo V. Multiple Myeloma. In: None. None. Nova Science Publishers, None, 2011.
- Quintas-Cardama A,, Kim TD, Cataldo V, Le Coutre. Nilotinib. In: None. 1st. None, None, 2010.
Books (edited and written)
- Quintas-Cardama A,, Gibbons D,, Cataldo V. Targeted Therapy for Solid Tumors and Hematologic Malignancies. Ed(s) None. Nova Science Publishers, 2011.
Letters to the Editor
- Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br J Haematol 195: e150-e153, 2021.
Selected Presentations & Talks
Local Presentations
- 2022. The Toxicities of Cancer Immunotherapy. Invited. New Orleans, Louisiana, US.
- 2019. A Primer on Immuno-Oncology. Invited. New Orleans, Louisiana, US.
- 2018. Current Strategies in Immuno-Oncology 2018, Keynote Address. Invited. New Orleans, Louisiana, US.
- 2015. A Rare Solid Phase of a Common Hematologic Malignancy. Poster. LSU Health Sciences Regional Research Day 2015. Baton Rouge, Louisiana, US.
- 2014. Cancer Screening: A Review of Current Evidence, 2014 Guidelines, and Controversies. Invited. Grand Rounds. Baton Rouge, Louisiana, US.
- 2014. Novel Approaches to Anticoagulation. Invited. Baton Rouge, Louisiana, US.
- 2013. Controversies in Cancer Screening. Invited. Mobile, Alabama, US.
- 2008. The Current Treatment Paradigm of Chronic Myeloid Leukemia. Invited. Grand Rounds. New Orleans, Louisiana, US.
- 2006. Commencement Speaker. Invited. Baton, Rouge, Louisiana, US.
- 2006. Hurricane Katrina. Invited. Grand Rounds. New Orleans, Louisiana, US.
Regional Presentations
- 2010. Diagnostic Dilemma Posed by Cerebrospinal Fluid Lymphocytic Pleocytosis in the Setting of Untreated Malignancy. None. Louisiana ACP Annual Meeting 2010. New Orleans, Louisiana, US.
- 2010. Diagnostic Dilemma Posed by Cerebrospinal Fluid Lymphocytic Pleocytosis in the Setting of Untreated Malignancy. None. Mississippi/Louisiana Regional ACP Meeting. Hattiesburg, Mississippi, US.
National Presentations
- 2019. SUCCESSOR Study: Baseline Demographics of the Retrospective, Noninterventional Follow-Up Study in a Subset of Patients with Sickle Cell Pain Crises Who Previously Participated in SUSTAIN in the United States. Invited. 42nd National Sickle Cell Disease Scientific Meeting. Fort Lauderdale, Florida, US.
- 2019. Health Care Resource Utilization and Rate of VOCs in Patients Who Previously Participated in the SUSTAIN Trial in the United States: The SUCCESSOR Study. Poster. Academy of Managed Care and Pharmacy Annual Meeting. San Diego, California, US.
- 2015. Massive Pulmonary Embolism: A Rare Presentation of Acute HIV-1 Infection. Poster. ACP National Conference 2015. Boston, Massachusetts, US.
- 2015. Massive Pulmonary Embolism: A Rare Presentation of Acute HIV-1 Infection. Poster. Louisiana/Mississippi ACP Conference. New Orleans, Louisiana, US.
- 2010. Diagnostic Dilemma Posed by Clinically Significant Sarcoidosis-associated Hypercalcemia in the Setting of Chronic Disease. Invited. American Thoracic Society Annual Meeting. New Orleans, Louisiana, US.
- 2009. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Invited. ASH Annual Meeting. New Orleans, Louisiana, US.
International Presentations
- 2019. SUCCESSOR: A Multicenter Retrospective Noninterventional Follow-Up Study in Patients with Sickle Cell Pain Crises Who Previously Participated in the SUSTAIN Trial in the United States. Invited. Amsterdam, NL.
- 2019. SUCCESSOR Study: Treatment and Health Care Resource Utilization by Sickle Cell Patients Who Participated in the SUSTAIN Study in the United States. Poster. New Orleans, US.
- 2010. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. Poster. ASCO Annual Meeting. Chicago, US.
- 2010. Bone Loss in Lymphoma Patients Prior to Receiving Frontline Therapy. None. 14th Annual International Congress on Hematologic Malignancies 2010. Whistler, CA.
Patient Reviews
CV information above last modified January 27, 2025